print version 

Find company
Home About the ProjectContact usFor the Clients
Enter code or ISIN
 
alpha / industry search

Issuers' Corner
Press Releases
Annual Reports Library

Financial Statements
SEC & FFMS Filings
Corporate Presentations
GM Materials
Issues Documents
Corporate Governance Materials
Russian Company Guide
Company Profiles
Corporate Calendar
Markets Corner
Consensus Estimates
Media Corner
News Line


Get updates



Home  Issuers' Corner  Press Releases REGISTER LOG IN

Press Releases

company search
all press releases
all Pharmstandard press releases

Pharmstandard

August 27, 2013

Pharmstandard Commits $30 Million to Argos Therapeutics Inc.

Moscow, August 27, 2013 – Pharmstandard OJSC (LSE: PHST LI, MICEX-RTS: PHST RU) (“Pharmstandard” or/and the “Company”) announces that its subsidiary Pharmstandard International S.A.(Luxembourg) (“Pharmstandard Int.”) has purchased  9,214,233 Series E Preferred Shares and 1,417,571 Warrants of Argos Therapeutics Inc. (“Argos”) for the amount of US$12m for the purpose of financing the ongoing ADAPT pivotal Phase 3 clinical study of AGS-003 for metastatic renal cell carcinoma (mRCC). Total consideration for the purchase for Pharmstandard Int. is US30m and is planned in 3 tranches. The last US$6m tranche is conditional to positive results in Argos’ Product Phase 3 clinical study. The total sum of financing for the first tranche secured by Argos for this clinical study amounts to US$42.5m.

Pharmstandard Int. was represented by Inbio Ventures – a management company that provides professional support for drug development activities in Russia and overseas. Alexandr Shuster, President of Inbio Ventures, said, “Our investment in Argos is a major component of the globalization of Pharmstandard’s operations and its focus on identifying innovative cell-based therapies.  Immunotherapy is increasingly recognized as a treatment that will represent a new paradigm in the management of cancer. We were impressed with the Argos science, management team and progress of its clinical trials in both cancer and HIV.”

Pharmstandard International S.A. - a holding company fully committed by Pharmstandard – is aimed to make venture investments in pharmaceutical companies based in North America and Europe with strategic focus on innovative drugs with a strong potential to cover yet unmet medical needs in Russia and CIS countries.

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos´ most advanced product candidate AGS-003 has initiated a Phase 3 study for the treatment of mRCC, and the Company plans to have data from its Phase 2b study of AGS-004 for the treatment of HIV in the first half of 2014. For more information about Argos Therapeutics, visit www.argostherapeutics.com.

Regards,                                                                                           
Irina Bakhturina
Investor Relations
Pharmstandard OJSC
Tel.   (495) 970-0030 ext.2824
Fax  (495) 970-0032
www.pharmstd.ru

 

 

 

Search by industry

Agriculture, Foresty and Fishing | Chemicals | Engineering | Ferrous Metals | Financial, Insurance & Real Estate | Food & Kindred Products | General Construction | Information Technology | Media & Publishing | Non-Ferrous Metals | Oil & Gas | Pharmaceuticals | Power Industry | Precious Metals and Diamonds | Telecommunications | Transportation | Wholesale & Retail Trade

Search by alpha index

A B C D F G H I K L M N O P R S T U V W X Z


Site Map
© RUSTOCKS.com
Privacy Statement | Disclaimer